Kailera Therapeutics G&A increased by 33.5% to $13.79M in Q1 2026 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ1 2025
Last reportedQ1 2026May 26, 2026
How to read this metric
Rising G&A as a percentage of revenue may indicate organizational bloat, while stability suggests effective cost management.
Detailed definition
General and administrative expenses cover the overhead costs of running the business, including executive salaries, lega...
Peer comparison
Standard operating expense category; used to assess administrative leverage.
Metric ID:
general_and_administrativeHistorical Data
2 periods
| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $10.33M | $13.79M |
| QoQ Change | — | +33.5% |
| YoY Change | — | +33.5% |
Range$10.33M – $13.79M
Avg YoY Growth+33.5%
Median YoY Growth+33.5%
G&A at Other Companies
Frequently Asked Questions
- What is Kailera Therapeutics 's g&a?
- Kailera Therapeutics (KLRA) reported g&a of $13.79M in Q1 2026.
- What does g&a mean?
- The overhead costs required to manage and support the company's operations.